Browse the evidence

Individuals with greater weight loss reported consuming higher proportions of low-energy-dense foods and lower proportions of high-energy-dense foods than individuals with less weight loss at 4 months and 18 months.

Encouraging the consumption of low-energy-dense foods may enhance weight loss outcomes.

At 18 months, individuals with greater weight loss had higher fruit and vegetable intake, dietary quality, nutrition knowledge, and healthier food choice.

Improving nutrition knowledge and food choices may support weight loss efforts.

Only nutrition knowledge and food choice were associated with weight loss at 18 months.

Focusing on enhancing nutrition knowledge and food choices can be crucial for weight loss success.

Time-dependent increases were detected from baseline to week 8 for muscle thickness and strength.

Resistance training leads to significant improvements in muscle thickness and strength over 8 weeks.

Emerging dietary factors such as glycemic index, fiber intake, dietary variety, and energy density may improve the efficacy and tolerability of energy restriction.

Incorporating these factors may enhance weight loss programs.

Being in the top versus bottom quartile of the carbohydrate quality index (CQI) is associated with a higher nutrient adequacy ratio (NAR) for folic acid (OR: 3.20), vitamin A (OR: 3.66), magnesium (OR: 5.94), and vitamin C (OR: 7.85).

Practitioners should consider promoting higher carbohydrate quality to improve micronutrient intake among adults.

Increasing the consumption of total fiber and solid carbohydrates while decreasing the glycemic index can improve micronutrient intake adequacy.

Dietary interventions should focus on fiber and solid carbohydrate intake to enhance micronutrient adequacy.

The article aims to analyze the roles and practical applications of amino acids in regulating body composition and performance in anaerobic and aerobic sports.

Insights from this analysis can guide training and nutrition strategies for athletes.

The use of long‐acting incretin‐based therapies, such as semaglutide, has increased due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.

Clinicians should consider the benefits of semaglutide for patients with diabetes and weight management needs.

Retatrutide exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).

Retatrutide may be an effective treatment option for managing HbA1c and weight in T2DM patients.

In non-T2DM individuals, retatrutide produced substantial weight loss and improved glucose levels.

Retatrutide may also benefit non-T2DM individuals seeking weight loss and improved glucose control.

Behavioral interventions and pharmacological therapies may be effective strategies for weight management in PWH.

Integrating behavioral and pharmacological approaches may enhance weight management efforts in PWH.

New glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been confirmed to reduce weight and preserve kidney function.

Clinicians may consider these new drugs as effective treatment options for managing ORG.

Addition of glucagon receptor agonism enhances weight loss, reduces liver fat, and ameliorates dyslipidemia.

Practitioners should consider glucagon receptor agonists for their potential benefits in weight loss and metabolic health.

SGLT-2 inhibitors and GLP-1 receptor agonists (GLP-1RAs) lead to a decline in body weight ranging from 1.5 to 5 kg.

Practitioners can consider SGLT-2 inhibitors and GLP-1RAs as effective options for weight loss in patients.

Liraglutide and semaglutide may provide benefits for weight loss and glycaemic control in people living with HIV.

Practitioners may consider liraglutide and semaglutide for weight management in HIV patients, particularly those with diabetes.

The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.

Practitioners should consider semaglutide as a treatment option for improving outcomes in obese HFpEF patients.

Obesity is a major risk factor for the development and progression of type 2 diabetes.

Addressing obesity is crucial for managing type 2 diabetes.

A healthy lifestyle is essential for the long-term success of any therapeutic intervention for obesity.

Encouraging lifestyle changes is vital for effective obesity treatment.

Practical recommendations for weight management should include supportive communication and shared decision-making.

Incorporating communication strategies can enhance weight management efforts.

The use of chains during resistance training (CRT) resulted in a 28% improvement in bench press 1RM compared to a 19% improvement with traditional resistance training (TRT).

Incorporating chains into resistance training may enhance strength gains more effectively than traditional methods.

Both CRT and TRT groups showed improvements in strength compared to the non-exercise control group (CG).

Both CRT and TRT are effective for improving strength in recreationally-trained individuals.

CRT led to an 8% improvement in back squat endurance, while TRT only showed a 2% improvement.

Using chains in resistance training may enhance muscular endurance more than traditional methods.

All groups showed significant improvements in cardiorespiratory fitness, upper body strength, lower body strength, and 2000m rowing performance.

Concurrent training can lead to significant improvements in fitness and strength regardless of protein supplementation.